An observation study on the long-term efficacy of Huisheng oral solution after radical operation of stage II to IIIb non-small cell lung cancer (NSCLC)

Sichuan Provincial People's Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. The patient's aged >=18 years, and the gender is not limited;
•2. Radical surgical treatment has been performed in the research center (Thoracic Surgery Department of Sichuan Provincial People's Hospital);
•3. On the 5 ± 3 days after the operation, pathological examination was diagnosed as non-small cell lung cancer, and according to the 8th edition of the International Society for the Study of Lung Cancer (IASLC) lung cancer TNM staging was stage II to IIIb;
•4. The investigator assessed complete remission (CR) after the operation;
•5. No history of allergies to the ingredients of Huisheng Oral Liquid in the past;
•6. Performance Status: 0-1 points;
•7. The life expectancy is at least 12 weeks;
•8. Laboratory examinations confirmed that the patient's blood routine and liver and kidney functions were normal within 7 days before the first medication;
•9. The patient must have the ability to understand and voluntarily sign an informed consent form.

•1. Merge other tumors;
•2. Those with a history of deep vein thrombosis, pulmonary embolism, stroke, acute myocardial infarction, atrial fibrillation, patent foramen ovale, etc.;
•3. Patients with bleeding tendency or coagulation disorders;
•4.6 Those who have suffered acute spinal cord injury, have undergone joint replacement surgery, and have multiple traumas to hip, pelvic or lower limb fractures within 4.6 months;
•5. Suffer from uncontrollable neurological, mental illness or mental disorder, and poor compliance;
•6. Patients who participate in other clinical trials at the same time;
•7. Other situations that the researcher thinks are not suitable for inclusion in the group.

发起方

Sichuan Provincial People's Hospital